Sugi Predict

Sugi Predict / Targets / CRACR2A

CRACR2A

EF-hand calcium-binding domain-containing protein 4B · Q9BSW2 · CRACR2A on Sugi Atlas →

5,027 patent compounds predicted against CRACR2A, 2,088 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1668067 SCHEMBL1668067 1.00 20/20
SCHEMBL1668206 SCHEMBL1668206 1.00 20/20
SCHEMBL1668276 SCHEMBL1668276 1.00 20/20
SCHEMBL1668354 SCHEMBL1668354 1.00 20/20
SCHEMBL1668851 SCHEMBL1668851 1.00 20/20
SCHEMBL1670439 SCHEMBL1670439 1.00 20/20
SCHEMBL1670537 SCHEMBL1670537 1.00 20/20
SCHEMBL1879487 SCHEMBL1879487 1.00 20/20
SCHEMBL1668055 SCHEMBL1668055 0.80 20/20
SCHEMBL1880364 SCHEMBL1880364 0.79 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1669276) 0.79 20/20
SCHEMBL1668140 SCHEMBL1668140 0.79 20/20
SCHEMBL1668237 SCHEMBL1668237 0.78 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1668012) 0.77 20/20
SCHEMBL1883613 SCHEMBL1883613 0.77 20/20
SCHEMBL1668193 SCHEMBL1668193 0.76 20/20
SCHEMBL1883285 SCHEMBL1883285 0.75 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1668798) 0.74 20/20
SCHEMBL1668025 SCHEMBL1668025 0.73 20/20
SCHEMBL1668949 SCHEMBL1668949 0.73 20/20

Clinical trials — most relevant to CRACR2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA PHASE4COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) PHASE2COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin nanCOMPLETED
Comparison of Two Methods to Diagnose Coronary Artery Disease nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines nanUNKNOWN
Stress and Treatment Response in Puerto Rican Children With Asthma nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer nanACTIVE_NOT_RECRUITING
Familial Intracranial Aneurysm Study II nanCOMPLETED
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
CCM Italian Registry nanUNKNOWN
Family Blood Pressure Program - GENOA nanCOMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Study Looking at the Recovery of New Onset Cardiomyopathy nanCOMPLETED
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2) nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CRACR2A binder may also engage these)

ProteinNameSimilarity
Q3UP38 — 0.996 Q3UP38 →
A1A600 — 0.991 A1A600 →
Q8K330 — 0.990 Q8K330 →
Q96ST8 — 0.990 Q96ST8 →
A6QNP9 — 0.989 A6QNP9 →
Q9CZX2 — 0.988 Q9CZX2 →
Q8TDY4 — 0.988 Q8TDY4 →
Q5XIS1 — 0.988 Q5XIS1 →
Q6PCQ0 — 0.988 Q6PCQ0 →
Q9BQI7 — 0.987 Q9BQI7 →
Q6ZSZ5 — 0.987 Q6ZSZ5 →
Q2TAA8 — 0.987 Q2TAA8 →
Q8N4X5 — 0.987 Q8N4X5 →
Q9H257 — 0.987 Q9H257 →
Q6ZQ12 — 0.987 Q6ZQ12 →
Q9Y4G2 — 0.987 Q9Y4G2 →
Q8BIJ7 — 0.987 Q8BIJ7 →
P58660 — 0.987 P58660 →
O95238 — 0.987 O95238 →
Q8CJ96 — 0.987 Q8CJ96 →
A2AIV8 — 0.987 A2AIV8 →
Q80VA5 — 0.987 Q80VA5 →
Q9D684 — 0.987 Q9D684 →
Q6P1I6 — 0.987 Q6P1I6 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.987 landscape →
Q2HJE1 — 0.986 Q2HJE1 →
B7ZNG0 — 0.986 B7ZNG0 →
Q9ULE4 — 0.986 Q9ULE4 →
Q8VDC1 — 0.986 Q8VDC1 →
Q8VDP4 — 0.986 Q8VDP4 →